CFM
RNAM

Catalyst Funds Management’s Avidity Biosciences RNAM Stock Holding History

Catalyst Funds Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,200
Closed -$30.6K – 1529
2024
Q1 		$30.6K Buy
+1,200
New +$18.8K 0.01% 660

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Catalyst Funds Management's RNAM Position: Q2 2024 in Review

Catalyst Funds Management sold out of Avidity Biosciences (RNAM) in Q2 2024, closing a stake of 1,200 shares — an estimated $30.6K sold.

Catalyst Funds Management first reported a position in RNAM in Q1 2024 and held it in 1 quarter. The position peaked at $30.6K in Q1 2024. 196 funds tracked by Wall St. Rank hold RNAM as of Q2 2024.

  • Catalyst Funds Management reported no remaining Avidity Biosciences position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,200 Avidity Biosciences shares in Q2 2024, an estimated $30.6K.
  • Catalyst Funds Management first reported a position in Avidity Biosciences in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Avidity Biosciences position peaked at $30.6K in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.